Portfolio News
Sofinnova Capital
Avantium reaches key commercial milestone for its FDCA flagship plant with commitments for >50% of its output
Avantium N.V., a leading technology company in renewable chemistry, announces that it has signed a conditional offtake agreement with Resilux, an international rigid plastic packaging supplier, for the supply of PEF resin from the planned Avantium FDCA flagship plant. This brings the total of such offtake contracts to five.
Related Strategy
Industrial BiotechRelated Company
AvantiumAMSTERDAM, 7 April 2021, 18:00 hrs CEST – Avantium N.V., a leading technology company in renewable chemistry, announces that it has signed a conditional offtake agreement with Resilux, an international rigid plastic packaging supplier, for the supply of PEF resin from the planned Avantium FDCA flagship plant. This brings the total of such offtake contracts to five.
The planned FDCA flagship plant is set to produce 5 kilotonnes of FDCA (furandicarboxylic acid) per annum, the key building block for the 100% fossil-free, recyclable polymer PEF (polyethylene furanoate). Including an additional commitment from one of the previously announced offtake partners, the five conditional offtake agreements represent a total offtake volume of over 50% of the FDCA production capacity from the flagship plant. This marks an important step towards a positive Final Investment Decision (FID) for the construction of the world’s first commercial FDCA plant, which Avantium would plan to open in 2023.
Related News
Genespire announces that GENE202 has been granted Orphan Drug Designation by the FDA and EC for the treatment of methylmalonic acidemia
SafeHeal® Announces Successful Launch of SAFE-3CV IDE Study for Colovac® Anastomosis Protection Technology
BrightHeart Raises €11M Series A to Scale Expert-Level AI Platform for Prenatal Ultrasound
Mediar Therapeutics Announces Oversubscribed $76 Million Series B Financing and Clinical Advancement of First-in-Class Fibrosis Portfolio
DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies